| 1 |
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal et al. · New England Journal of Medicine
|
12 Apr 2014 |
1,312 |
| 2 |
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Péter Ferenci et al. · New England Journal of Medicine
Open access |
4 May 2014 |
697 |
| 3 |
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
David R. Nelson et al. · Hepatology
Open access |
23 Jan 2015 |
694 |
| 4 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Marc Bourlière et al. · New England Journal of Medicine
|
31 May 2017 |
571 |
| 5 |
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al. · Journal of Hepatology
640 authors |
5 Mar 2020 |
494 |
| 6 |
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Seth Loomba et al. · Hepatology
|
10 Nov 2020 |
290 |
| 7 |
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin Mark Anstee et al. · Hepatology
|
4 Jul 2019 |
276 |
| 8 |
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy et al. · Gastroenterology
Open access |
8 Aug 2020 |
271 |
| 9 |
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison, Zachary D Goodman, Abdul Jabbar et al. · Journal of Hepatology
|
27 Dec 2019 |
260 |
| 10 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
Jordan J. Feld, Christophe Moreno, Roger N. Trinh et al. · Journal of Hepatology
Open access |
25 Oct 2015 |
162 |
| 11 |
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Guadalupe García–Tsao et al. · Journal of Hepatology
Open access |
21 Dec 2019 |
160 |
| 12 |
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A Harrison et al. · The Lancet. Gastroenterology & hepatology
|
21 Mar 2022 |
137 |
| 13 |
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
Zobair M. Younossi, Mazen Noureddin, David Eliot Bernstein et al. · The American Journal of Gastroenterology
Open access |
6 Dec 2020 |
106 |
| 14 |
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
Mohammad Shadab Siddiqui, Michael O. Idowu, Dhruvanshu Parmar et al. · Clinical Gastroenterology and Hepatology
|
2 Nov 2020 |
92 |
| 15 |
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Mary Eugenia Rinella, Hsiao Dee Lieu, Kris V. Kowdley et al. · Hepatology
Open access |
21 Sep 2023 |
90 |
| 16 |
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
David L. Wyles, Paul J. Pockros, Giuseppe Morelli et al. · Hepatology
|
2 Apr 2015 |
89 |
| 17 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz et al. · Gastroenterology
Open access |
31 Jul 2016 |
53 |
| 18 |
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
Stefan Schreiber, Corey Allan Siegel, Keith Friedenberg et al. · Journal of Crohn s and Colitis
Open access |
28 May 2018 |
52 |
| 19 |
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease
William J. Sandborn, Bal Raj Bhandari, Charles W. Randall et al. · Journal of Crohn s and Colitis
Open access |
13 May 2018 |
50 |
| 20 |
Clinical triage decision vs risk scores in predicting the need for endotherapy in upper gastrointestinal bleeding
Farees T. Farooq, Michael Ho-Yan Lee, Ananya Das et al. · The American Journal of Emergency Medicine
|
25 Dec 2010 |
50 |
| 21 |
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
Donald M. Jensen et al. · Journal of Hepatology
|
19 Feb 2015 |
46 |
| 22 |
Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C
Jean-Pierre Bronowicki et al. · Antiviral Therapy
Open access |
26 Jun 2013 |
46 |
| 23 |
The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
Edward John Gane, Sophie Métivier, Ronald Nahass et al. · Hepatology Communications
Open access |
22 Jun 2017 |
42 |
| 24 |
Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease
Valeriya Pozdnyakova et al. · Gastroenterology
Open access |
12 Aug 2021 |
34 |
| 25 |
Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease
GIL Y. MELMED et al. · The American Journal of Gastroenterology
Open access |
19 Nov 2021 |
32 |
| 26 |
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
Vincent Wai‐Sun Wong, Won Young Tak, George Boon‐Bee Goh et al. · Clinical Gastroenterology and Hepatology
Open access |
22 Jan 2022 |
29 |
| 27 |
Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
Fred F Poordad, Kosh Agarwal, Ziad H Younes et al. · Clinical Infectious Diseases
Open access |
2 Nov 2014 |
27 |
| 28 |
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
Stephen A. Harrison, Seth J. Baum, Nadege Gunn et al. · The American Journal of Gastroenterology
Open access |
12 Aug 2021 |
26 |
| 29 |
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
Jean–Pierre Bronowicki, Vlad Ratziu, Adrian Carlos Gadano et al. · Journal of Hepatology
|
16 Jul 2014 |
25 |
| 30 |
Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway
Caroline Hwang, Kelly Issokson, Catherine Giguere‐Rich et al. · Clinical Gastroenterology and Hepatology
|
26 Jun 2020 |
23 |
| 31 |
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis
Sven Francque, Alexander D. Hodge, Jérôme Boursier et al. · Hepatology Communications
Open access |
29 Jan 2024 |
15 |
| 32 |
Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
Dalin Li et al. · Inflammatory Bowel Diseases
Open access |
23 Aug 2022 |
14 |
| 33 |
1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016)
J.‐P. Bronowicki, Vlad Ratziu, Adrian Carlos Gadano et al. · Journal of Hepatology
Open access |
Apr 2013 |
11 |
| 34 |
Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease
Christopher V. Almario et al. · The American Journal of Gastroenterology
Open access |
3 Nov 2021 |
10 |
| 35 |
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes
Zobair M. Younossi, Maria A. Stepanova, Ira M. Jacobson et al. · Clinical Infectious Diseases
Open access |
Apr 2019 |
10 |
| 36 |
Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
Rohit Seth Loomba et al. · Journal of Hepatology
|
Aug 2020 |
9 |
| 37 |
The Effect of EndocuffTM—-Assisted Colonoscopy on Adenoma Detection Rate: A Randomized Trial in Community Ambulatory Surgical Centers
Edward L. Cattau, Rolando J. Leal, Eric J. Ormseth et al. · The American Journal of Gastroenterology
|
Oct 2015 |
9 |
| 38 |
Hypervascular lesions of the pancreas: Think before you act
Susan M. Wcislak, Zachary E. Stiles, Jeremiah Lee Deneve et al. · The American Journal of Surgery
|
27 Nov 2018 |
9 |
| 39 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy
Fred F Poordad, MICHAEL R. BENNETT, Thomas E. Sepe et al. · Journal of Medical Virology
|
6 Mar 2019 |
7 |
| 40 |
Reinduction with Certolizumab Pegol in Patients with Crohnʼs Disease Experiencing Disease Exacerbation
Scott David Lee, David T. Rubin, William J. Sandborn et al. · Inflammatory Bowel Diseases
Open access |
9 Jul 2016 |
7 |
| 41 |
A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma
David J. Taggart et al. · Journal of Hepatology
Open access |
6 May 2026 |
5 |
| 42 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
Jordan J. Feld, David E. Bernstein, Ziad H Younes et al. · Liver International
Open access |
29 Jan 2018 |
5 |
| 43 |
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Yoo Jin Lee et al. · Inflammatory Bowel Diseases
Open access |
29 Sep 2023 |
2 |
| 44 |
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies
Stuart C. Gordon, Alejandra Villamil, Ira M. Jacobson et al. · Hepatology Communications
Open access |
13 Apr 2026 |
1 |
| 45 |
Integrated IBD Care in the Community: Evaluating Sustainable Models and Building a Framework for the Future
Erica R. Cohen, Timothy Ritter, William H. Holderman et al. · Gastroenterology
|
20 Nov 2025 |
1 |
| 46 |
Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Liver Cirrhosis in the Open-Label, Long-Term ASSURE Safety Study: Interim Results
Stuart R. Gordon, Ira M. Jacobson, Ziad H Younes et al. · Zeitschrift für Gastroenterologie
Conference paper |
2025 |
1 |
| 47 |
The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
Mazen Noureddin et al. · Journal of Hepatology
|
Jul 2022 |
1 |
| 48 |
Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy et al. · Journal of Hepatology
|
Aug 2020 |
1 |
| 49 |
IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials
Vincent Wai‐Sun Wong et al.
Conference paperOpen access |
Jun 2019 |
1 |
| 50 |
Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials
Pietro Lampertico et al. · Digestive and Liver Disease
|
Feb 2019 |
1 |